There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | David Inman |
| Institution: | GSK |
| Department: | Biostatistics |
| Country: | |
| Proposed Analysis: | GSK is conducting a Phase II trial in Alzheimer's Disease and are looking to utilize the ADNI data to: Support study design assumptions Evaluate the potential use of concurrent control data to support progression decisions including but not limited to historical data borrowing, prognostic covariate modelling and disease progression models. Analyze cross sectional and longitudinal changes in biomarkers in different subgroups to evaluate natural history and correlate with clinical covariates. |
| Additional Investigators | |
| Investigator's Name: | David Lunn |
| Proposed Analysis: | As per primary investigator. |
| Investigator's Name: | Doug Thompson |
| Proposed Analysis: | GSK is conducting a Phase II trial in Alzheimer's Disease and are looking to utilize the ADNI data to: Support study design assumptions Evaluate the potential use of concurrent control data to support progression decisions including but not limited to historical data borrowing, prognostic covariate modelling and disease progression models. Analyze cross sectional and longitudinal changes in biomarkers in different subgroups to evaluate natural history and correlate with clinical covariates. |
| Investigator's Name: | Paul Newcombe |
| Proposed Analysis: | GSK is conducting a Phase II trial in Alzheimer's Disease and are looking to utilize the ADNI data to: Support study design assumptions Evaluate the potential use of concurrent control data to support progression decisions including but not limited to historical data borrowing, prognostic covariate modelling and disease progression models. Analyze cross sectional and longitudinal changes in biomarkers in different subgroups to evaluate natural history and correlate with clinical covariates. |
| Investigator's Name: | Tom Taverner |
| Proposed Analysis: | GSK is conducting a Phase II trial in Alzheimer's Disease and are looking to utilize the ADNI data to: Support study design assumptions Evaluate the potential use of concurrent control data to support progression decisions including but not limited to historical data borrowing, prognostic covariate modelling and disease progression models. Analyze cross sectional and longitudinal changes in biomarkers in different subgroups to evaluate natural history and correlate with clinical covariates. |
| Investigator's Name: | Aris Perperoglou |
| Proposed Analysis: | GSK is conducting a Phase II trial in Alzheimer's Disease and are looking to utilize the ADNI data to: Support study design assumptions Evaluate the potential use of concurrent control data to support progression decisions including but not limited to historical data borrowing, prognostic covariate modelling and disease progression models. Analyze cross sectional and longitudinal changes in biomarkers in different subgroups to evaluate natural history and correlate with clinical covariates. |
| Investigator's Name: | Nakul Kamath |
| Proposed Analysis: | GSK is conducting a Phase II trial in Alzheimer's Disease and are looking to utilize the ADNI data to: Support study design assumptions Evaluate the potential use of concurrent control data to support progression decisions including but not limited to historical data borrowing, prognostic covariate modelling and disease progression models. Analyze cross sectional and longitudinal changes in biomarkers in different subgroups to evaluate natural history and correlate with clinical covariates. |
| Investigator's Name: | Harry Parr |
| Proposed Analysis: | GSK is conducting a Phase II trial in Alzheimer's Disease and are looking to utilize the ADNI data to: Support study design assumptions Evaluate the potential use of concurrent control data to support progression decisions including but not limited to historical data borrowing, prognostic covariate modelling and disease progression models. Analyze cross sectional and longitudinal changes in biomarkers in different subgroups to evaluate natural history and correlate with clinical covariates. |
| Investigator's Name: | Dimitra Brintziki |
| Proposed Analysis: | GSK is conducting a Phase II trial in Alzheimer's Disease and are looking to utilize the ADNI data to: Support study design assumptions Evaluate the potential use of concurrent control data to support progression decisions including but not limited to historical data borrowing, prognostic covariate modelling and disease progression models. Analyze cross sectional and longitudinal changes in biomarkers in different subgroups to evaluate natural history and correlate with clinical covariates. |
| Investigator's Name: | Jeffrey Lin |
| Proposed Analysis: | GSK is conducting a Phase II trial in Alzheimer's Disease and are looking to utilize the ADNI data to: Support study design assumptions Evaluate the potential use of concurrent control data to support progression decisions including but not limited to historical data borrowing, prognostic covariate modelling and disease progression models. Analyze cross sectional and longitudinal changes in biomarkers in different subgroups to evaluate natural history and correlate with clinical covariates. |
